Once-weekly DPP-4 inhibitor, ‘omarigliptin,’ to be launched in the domestic market
A once-weekly DPP-4 inhibitor diabetes treatment will enter the domestic market.
According to the industry concerned on the 21st, MSD Korea has prepared for the domestic launch of a DPP-4 inhibitor using ‘omarigliptin’ as the main substance.
The drug, a once-weekly oral diabetes-treating DPP-4 ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
